- Silo Pharma recently provided an update on an ongoing study delving into the potential use of SPU-21 joint homing peptides as an alternative treatment for rheumatoid arthritis
- The study, which is being carried out in conjunction with the University of Maryland, Baltimore, has resulted in positive initial results
- Since its founding, Silo Pharma has rapidly gained a reputation for its innovative approach towards seeking solutions to address a variety of underserved medical conditions
Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused around merging traditional therapeutics with psychedelic research, recently revealed the positive interim data from its dose optimization study of SPU-21 joint homing peptides for subcutaneous administration of anti-arthritic agents. The results come after the biopharmaceutical company initiated a pilot study on its novel joint homing peptides targeting rheumatoid arthritis in late November, specifically looking into the binding affinity of the peptide in healthy human and RA synovial tissue.
At the time, Eric Weisblum, Chief Executive Officer of Silo Pharma explained the rationale underpinning the study, “SPU-21 was shown to inhibit arthritic progression in a preclinical animal model, so we are proceeding to advance our research into human synovial tissue, where we will first assess binding affinity. Positive data from this important study could support further research into the interaction of our joint homing peptide as a potential therapy for autoimmune disorders such as rheumatoid arthritis and inflammation.”
Rheumatoid arthritis is among the most common autoimmune diseases in the U.S., affecting approximately 1.5 Americans. A 2022 report published by Precedence Research revealed that the global rheumatoid arthritis drugs market was expected to reach $70 billion by 2030, growing at a compound annual growth rate of 1.7% (https://ibn.fm/S8bqi).
Although historically treated using DMARDs (disease-modifying antirheumatic drugs) or steroids, Silo Pharma has sought to advance the use of liposomal homing peptides as an alternative treatment for rheumatoid arthritis, with a positive test result from the ongoing study potentially acting as justification for further investigation.
Silo Pharma provided an update on the ongoing study as of December 30, 2022. During the study, tests were conducted to evaluate the disease-suppressive effects of an SPU-21 peptide-guided anti-arthritis drug versus the drug alone. The drug used in the study was dexamethasone (“DEX”), a corticosteroid used for its anti-inflammatory and immunosuppressant effects. Earlier results of the same study successfully demonstrated that the subcutaneous (“SC”) route of liposomal administration (small needle injection into shallow soft tissue just under the layer of skin) was-suited for use in targeted drug delivery of anti-arthritic agents (https://ibn.fm/h5fq6).
“We believe that the positive results of these latest tests show that our peptide with DEX given subcutaneously was effective in controlling arthritis progression. The effect of lipo-DEX was superior to that of DEX alone when both were administered via the SC route,” elaborated Eric Weisblum. “Since patients widely prefer SC administration over intravenous (‘IV’) infusion for multiple reasons, we believe the superiority and practicality of our liposomal joint homing peptide bode well for broad market potential. Meanwhile, we continue to explore other novel therapeutics for optimal pairing with SPU-21, targeting rheumatoid arthritis as our initial indication.”
Originally founded in 2010, Silo Pharma has rapidly earned a reputation in recent years for its ground-breaking research into conditions such as post-traumatic stress disorder (“PTSD”), fibromyalgia, Alzheimer’s disease, Parkinson’s disease, and other rare neurological disorders. Whilst promising in nature, the company’s study into joint-homing peptides, which it is carrying out in conjunction with the University of Maryland, Baltimore, is just one of a multitude of promising initiatives Silo Pharma is currently pursuing. Other projects also include a study focused around assessing the effect of psilocybin on inflammation being carried out with the University of California, San Francisco (“UCSF”) as well as an agreement with Columbia University, with both entities jointly exploring the use of prophylactic treatment for stress-induced disorders and PTSD (https://ibn.fm/YWacO).
For more information, visit the company’s website at www.SiloPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to SILO are available in the company’s newsroom at https://ibn.fm/SILO
About MissionIR
MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
For more information, visit www.MissionIR.com
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all
